Plain-English translation of NCT06051695 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing two versions of a new treatment called logic-gated CAR T-cell therapy ( or ) for people with advanced solid cancers—such as lung, colon, pancreatic, ovarian, or mesothelioma—that have not responded to standard care. The treatment works by taking your own immune cells, engineering them to recognize and attack cancer cells, and then infusing them back into your body. The therapy is designed with a built-in safety feature that protects healthy tissue from damage.
Current treatments for advanced solid tumors are often toxic and rarely cure the disease. This medication aims to offer a new approach by using your own immune system to fight cancer while reducing harm to healthy cells—something previous solid tumor therapies have struggled to achieve.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive a chemotherapy regimen to prepare your body, followed by a single infusion of the engineered immune cells. The trial involves visits to monitor your safety and how well the treatment is working, including blood tests and imaging scans. You will need to commit to long-term follow-up appointments to track how you respond and watch for any side effects. The study spans Phase 1 (to find the safe dose) and Phase 2 (to measure how well the treatment works).
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States